The Turkish professor claims income from weight loss shots now far exceeds total AI revenue, a comparison he makes without sourcing in the snippet.
Recap by typeshit. Post by Prof. Dr. Güner Sönmez on X.
About half of Australia's roughly 500,000 GLP-1 users pay privately, A$200 to $700 a month, and the authors argue cost hits those with the most obesity hardest.
Ireland's drug pricing body recommended semaglutide over tirzepatide for cost reasons, and Higgins says it's the right call, with a pun he didn't get to use.
Researchers tracked 8,914 insured patients in JAMA Health Forum. Above $75 out of pocket, nonadherence topped 80%, says author Eunhae Shin.
Costco is adding Novo Nordisk's semaglutide shots to what it offers. Details are thin here, so tap through for how pricing and access will work.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
Loading…